StaffEmanuela Pedrazzini


Informations



E-mail
pedrazzini@ibba.cnr.it

Phone
+39 0223699443

Office
Milano

Research area
BIOTEC, BIOCEL


ORCID: 0000-0002-9238-3840
Scopus Author ID: 6603869980

Pedrazzini Emanuela

Senior Researcher

Education

1999: PhD in Pharmacology and Toxicology, University of Milan

1989: Degree in Biological Science, University of Milan

Professional experience

2019 – Now:  Senior Researcher – CNR, Institute of Agricultural Biology and Biotechnology, Milan

2001 – 2019: Researcher – CNR, Institute of Agricultural Biology and Biotechnology, Milan

2006 – 2014: Professor on annual contract in Cellular Engineering –  University of Milano, Faculty of Agriculture, for the Master Degree in Plant Biotechnology

2001 – 2006: Tutoring activity for the Master Degree in Plant Biotechnology – University of Milano, Faculty of Agriculture

1995 – 1997: Lecturer – Theoretical – Practical courses on Biotechnology Applied to Pharmacology, University of Milan – Faculty of Medicine and Surgery

Research interests

  • Biogenesis and evolution of cellular compartments, mainly focused on synthesis and deposition of seed storage proteins: protein body biogenesis in cereal seeds, nutritional quality, allergenic/antinutritional potential
  • Endoplasmic Reticulum Quality Control (ERQC) and Unfolded Protein Response (UPR) in plants
  • Membrane protein synthesis, sorting and targeting (channels; tail-anchored proteins)
  • Comparative Cell Biology (Tonoplast vs Lysosomal membrane Proteostasis)
  • Molecular farming: production of recombinant pharmaceuticals/industrial proteins in plant systems
  • Scientific culture dissemination

Projects in progress

Climate change: risk mitigation for sustainable development
Start date: 01/11/2019   End date: 31/12/2022

MIUR

Milano, Lodi, Pisa
Emanuela Pedrazzini

Project duration:
01/11/2019 - 31/12/2022
Financing body:
MIUR
Project research leader:
Emanuela Pedrazzini
Headquarters:
Milano, Lodi, Pisa

Climate change: risk mitigation for sustainable development


The project includes:

  • Climate change impact on the sustainability and productivity of agricultural systems and adaptation strategies.
  • Use of genetic diversity of agricultural species for adaptation to climate change.
  • Production of new germplasm with enhanced drought tolerance, maintaining plant productivity and seed quality.
  •  The knowledge of the mechanisms involved in plant response to climate change will allow the development of strategies aimed at contrasting adverse environmental conditions.
  • Obtaining/identifying genotypes and genetic determinants for tolerance to abiotic (better water use efficiency, resistance to high temperatures) and nutritional (better nitrogen use efficiency) stresses.
  • Sustainability of farming systems and identification of genomic regions with an effect on adaptation in animals.
PREP-IBISBA - Industrial Biotechnology Innovation and Synthetic Biology Accelerator - Preparatory Phase
Start date: 01/01/2020   End date: 31/12/2023

H2020-EU.1.4. - EXCELLENT SCIENCE - Research Infrastructures

Milano   Website

Emanuela Pedrazzini, Aldo Ceriotti

Project duration:
01/01/2020 - 31/12/2023
Financing body:
H2020-EU.1.4. - EXCELLENT SCIENCE - Research Infrastructures
Project research leader:
Emanuela Pedrazzini, Aldo Ceriotti
Headquarters:
Milano
Project website:
Website

PREP-IBISBA - Industrial Biotechnology Innovation and Synthetic Biology Accelerator - Preparatory Phase


EU-IBISBA is a distributed research infrastructure concept that will deliver translational research and innovation services to the research community and industry alike. Its aim is to accelerate the movement of knowledge and early stage research results towards maturity and uptake for further development by industrial R&I. EU-IBISBA’s expertise is within the field of industrial biotechnology and focuses on the integrated development of bioprocesses, using a multidisciplinary approach and advanced technology such as synthetic biology.

PREP-IBISBA intervenes just after the addition of EU-IBISBA on the ESFRI roadmap and as a follow-up to an ongoing H2020 INFRAIA starting community project entitled IBISBA 1.0. The aim of PREP-IBISBA is to create the conditions to launch EU-IBISBA. It will deliver all the conceptual elements necessary to finalize the science and technology case and define the business model, establish a long range financial plan and identify alternative legal frameworks suitable to deliver EU-IBISBA. Overall, the work will lead to the creation of a legal entity, preferentially either an ERIC or another suitable legal instrument.

IBISBA 1.0 – Design Phase. Industrial Biotechnology Innovation and Synthetic Biology Accelerator
Start date: 01/12/2017   End date: 31/05/2022

Unione Europea

Milano, Lodi   Website

Emanuela Pedrazzini

Project duration:
01/12/2017 - 31/05/2022
Financing body:
Unione Europea
Project research leader:
Emanuela Pedrazzini
Headquarters:
Milano, Lodi
Project website:
Website

IBISBA 1.0 – Design Phase. Industrial Biotechnology Innovation and Synthetic Biology Accelerator


IBISBA 1.0 provides a coordinated network of research facilities to promote R&D in bioprocess development and support the bioeconomy. The facilities cover a wide range of experimental and in silico operations and disciplines, and together represent an R&D continuum to build quality biomanufacturing processes for industrialisation. IBISBA 1.0 aims at establishing an interoperable network of infrastructures capable of proposing R&D services to industrial biotechnology professionals. In this respect, IBISBA 1.0 has launched a Transnational Access (TNA) programme, which is conducted in the framework of open calls for projects.

sPATIALS3 - Improvement of agrifood productions and innovative technologies for a safer and more secure and sustainable nutrition
Start date: 01/02/2020   End date: 31/07/2022

Regione Lombardia

Milano, Lodi   Website

Francesca Sparvoli

Project duration:
01/02/2020 - 31/07/2022
Financing body:
Regione Lombardia
Project research leader:
Francesca Sparvoli
Headquarters:
Milano, Lodi
Project website:
Website

sPATIALS3 - Improvement of agrifood productions and innovative technologies for a safer and more secure and sustainable nutrition


sPATIALS3 is a technological and research hub involving 12 CNR Institutes belonging to 4 different Departments and 4 companies. Main objectives will be: obtainment of innovative food products improved for their nutritional and functional properties; provision and implementation of precision technologies to guarantee products quality, safety and traceability; development of innovative and eco-sustainable smart– and active-packaging to minimize and reuse wastes, where possible, and to increase food preservability; provision to consumers and producers of tools for results exploitation.

Projects completed

PlanOVac - Plant-based bio-encapsulation strategies for oral veterinary vaccines
Start date: 01/03/2019   End date: 01/07/2019

IBISBA 1.0

Milano   Website

Emanuela Pedrazzini

Project duration:
01/03/2019 - 01/07/2019
Financing body:
IBISBA 1.0
Project research leader:
Emanuela Pedrazzini
Headquarters:
Milano
Project website:
Website

PlanOVac - Plant-based bio-encapsulation strategies for oral veterinary vaccines


The project involves optimization of strategies to encapsulate vaccine and drug using storage proteins from maize seeds (zeins) as scaffolds. Zeins are generally considered safe and can also provide adjuvant effects for vaccines.
VaTEP - Vacuolar Transport Equipment for Growth Regulation in Plant
Start date: 01/10/2006   End date: 30/09/2010

Unione Europea

Milano   Website

Emanuela Pedrazzini

Project duration:
01/10/2006 - 30/09/2010
Financing body:
Unione Europea
Project research leader:
Emanuela Pedrazzini
Headquarters:
Milano
Project website:
Website

VaTEP - Vacuolar Transport Equipment for Growth Regulation in Plant


The tonoplast (the membrane of the plant vacuole) plays a central role in plant growth and cellular homeostasis. The VaTEP research network has focused on the role of tonoplast channels and transporters to identify their specific functions with respect to plant development and growth processes. The studies were carried out in an interdisciplinary manner by the various participating groups, and particular attention was given to the training of young researchers.
Synthesis and accumulation, in plant cells, of chimeric proteins for biotechnological uses
Start date: 31/03/2019   End date: 31/07/2019

Arterra Bioscience S.R.L.

Milano
Emanuela Pedrazzini

Project duration:
31/03/2019 - 31/07/2019
Financing body:
Arterra Bioscience S.R.L.
Project research leader:
Emanuela Pedrazzini
Headquarters:
Milano

Synthesis and accumulation, in plant cells, of chimeric proteins for biotechnological uses


Protein engineering service: Production of engineered constructs (plasmids) and verification of synthesis and accumulation, in plant cells, of chimeric proteins for biotechnological purposes.
PHARMAPLANT - Recombinant Pharmaceuticals from Plants for Human Health
Start date: 01/02/2004   End date: 30/01/2009

FP6-LIFESCIHEALTH

Milano   Website

Emanuela Pedrazzini

Project duration:
01/02/2004 - 30/01/2009
Financing body:
FP6-LIFESCIHEALTH
Project research leader:
Emanuela Pedrazzini
Headquarters:
Milano
Project website:
Website

PHARMAPLANT - Recombinant Pharmaceuticals from Plants for Human Health


Plants are attractive vehicles for the expression of recombinant pharmaceutical proteins as they are inexpensive and versatile systems, amenable to rapid and economical scale-up. Public opinion in Europe is generally negative towards GM plants, which has led to the loss of many SMEs and commercial development from the Union. However, the use of GM plants for medicines and vaccines rates very highly in terms of public acceptance. With this proposal, our primary aim is to build on previous proof-of-concept studies to develop pharmaceutical products through to clinical trials. The use of GM pharmaceuticals has precedents, such as human insulin and hepatitis B vaccine, but plant-derived materials used in humans has not been formally addressed within the EU. A major outcome will be to define the regulatory requirements through a process of engagement and consultation with all relevant regulatory bodies (involved in GM plants as well as new pharmaceuticals), in order to move through clinical trials and gain permission for the use of plant derived pharmaceuticals in practice. Monoclonal antibodies will be the first generation of molecules to be developed for Phase I clinical evaluation, and we include 2 neutralising antibodies each for HIV and rabies. The proposal also includes a limited range of other targets, against HIV, TB and diabetes, and for some of these, new expression strategies will need to be developed. They represent the second-generation molecules, which will feed the development pipeline for SMEs in Europe, beyond the lifetime of the project. In each case, plant-based systems offer a real advantage, if not the only option for production on a scale relevant to the needs for that molecule. Alongside our principle aim of developing plant derived recombinant pharmaceuticals, we recognise the need to put in place comprehensive risk assessments based on health and environmental impacts, and to work with EU regulatory authorities
Identification of a rapid test for anti-nutritional factors in vegetable protein flours
Start date: 08/05/2019   End date: 21/09/2019

Fa.Ma.Vit. S.p.A.

Milano
Emanuela Pedrazzini

Project duration:
08/05/2019 - 21/09/2019
Financing body:
Fa.Ma.Vit. S.p.A.
Project research leader:
Emanuela Pedrazzini
Headquarters:
Milano

Identification of a rapid test for anti-nutritional factors in vegetable protein flours


The project includes the development of a rapid assay for the determination of trypsin inhibitors in different soybean matrices (extracted soybean, extruded soybean, fermented concentrated protein soybean); the development of a rapid assay for the determination of allergens in different soya matrices; the molecular characterization of 3 soya matrices (extracted soy flour, extruded soy, fermented protein soy).

Istituto

Search website